Pharmaron Beijing Co Ltd
HKEX:3759
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (27.6), the stock would be worth HK$22.41 (9% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 25.3 | HK$20.58 |
0%
|
| 3-Year Average | 27.6 | HK$22.41 |
+9%
|
| 5-Year Average | 32.9 | HK$26.79 |
+30%
|
| Industry Average | 26.8 | HK$21.76 |
+6%
|
| Country Average | 28.9 | HK$23.51 |
+14%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
HK$54.4B
|
/ |
Jan 2026
¥2.1B
|
= |
|
|
HK$54.4B
|
/ |
Dec 2026
¥2.7B
|
= |
|
|
HK$54.4B
|
/ |
Dec 2027
¥3.2B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Pharmaron Beijing Co Ltd
HKEX:3759
|
52.7B HKD | 25.3 | 31.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
1T USD | 2 361.7 | 4 280.5 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
176.7B USD | 24.7 | 26.4 | |
| US |
|
Danaher Corp
NYSE:DHR
|
125.4B USD | 25.9 | 34 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 39.4 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
298.9B CNY | 16.3 | 15.6 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
34.3B CHF | 25.4 | -118.2 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 22 | 25.3 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.4B USD | 38.4 | 47.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
27.5B USD | 17.2 | 20.3 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26.1B USD | 24.7 | 30 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Pharmaron Beijing Co Ltd
Glance View
Pharmaron Beijing Co Ltd., a dynamic player in the biotech and pharmaceutical services sector, has carved a niche by capitalizing on the demand for comprehensive R&D services. Founded in 2004, the company emerged at a time when global pharmaceutical companies were grappling with skyrocketing research costs and the increasing complexity of drug development. Pharmaron offers a broad spectrum of services across the drug discovery and development pipeline, including laboratory services, chemistry, biology, and pharmacology, effectively monetizing its expertise by partnering with global pharmaceutical firms. By providing integrated solutions that cover the entire span of research, from preclinical development to commercial manufacturing, Pharmaron positions itself as an indispensable ally for companies aiming to streamline their product development journeys. The company’s revenue model thrives on long-term partnerships and collaborations with some of the industry's leading pharmaceutical and biotech firms. Using a client-centric approach, Pharmaron aligns its capabilities with customer needs, ensuring scalable and customizable service offerings. This close alignment not only enhances client satisfaction but also encourages repeat business, fostering a cycle of sustainable revenue growth. In recent years, Pharmaron has been expanding its geographical footprint and service capacity through strategic acquisitions and investments in state-of-the-art facilities and technologies, aiming to bolster its position in key markets across the US, Europe, and China. As the pharmaceutical landscape continues to evolve, Pharmaron leverages its robust R&D service portfolio and strategic alliances to maintain its growth trajectory amidst a backdrop of increasing globalization and technological advancement in the industry.